<DOC>
	<DOCNO>NCT00837824</DOCNO>
	<brief_summary>This study design determine appropriate treatment Fabrazyme biweekly dose either 1 mg/kg 3 mg/kg population patient severe renal disease burden .</brief_summary>
	<brief_title>Severe Renal Disease Study Fabry Patients Treated With Fabrazyme</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Fabry Disease</mesh_term>
	<criteria>provide write informed consent prior studyrelated procedure perform . ≥16 year old . current diagnosis Fabry disease ( define abnormal αgalactosidase ( α GAL ) enzyme level Fabry genotype ) . one follow clinical condition present enrollment : serum creatinine level great 3.0 mg/dL ( average two value least one week apart ) , currently dialysis , status post kidney transplant great 3 month . ability comply requirement protocol negative pregnancy test , female patient childbearing potential . In addition , female patient childbearing potential must use medically accept method contraception throughout study . meet specific inclusion criterion . participate study employ investigational drug within 30 day start participation trial . previously receive enzyme replacement therapy ( ERT ) Fabry disease . diabetic nephropathy . pregnant lactating . unwilling comply requirement protocol .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Fabry Disease patient Severe Renal Disease</keyword>
</DOC>